RadNet stock cooled slightly after the earnings release, slipping about 1% to US$76.34, yet the story behind the move is far from weak. The company just posted record Q2 2026 revenue of US$622.7m and delivered US$99.7m in adjusted earnings before interest, tax, depreciation and amortisation. That kind of top line and cash earnings power matters more than a single red day on the screen.

For anyone thinking beyond this week, the key question now is how those record imaging and digital health numbers fit into RadNet’s longer term growth and valuation debate.

Love RadNet's record revenue and cash earnings, but want more stocks with similar financial strength on your radar? Check out our curated list of list of solid balance sheet and fundamentals stocks (48 results).

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$622.72m vs. US$498.23m (up about 25%)
• Net Income (Excl. Extra Items, Q2 2026 vs. Q2 2025): US$7.53m vs. US$14.45m (down about 48%)
• Basic EPS (Q2 2026 vs. Q2 2025): US$0.10 per share vs. US$0.19 per share (down about 50%)
• Digital Health Annual Recurring Revenue (ARR, Q2 2026 vs. Q2 2025): US$105.5m vs. about US$53.6m (up about 97%)

Prefer clean, visual charts over reading through dense walls of earnings tables and footnotes? Get a complete view of RadNet's recent financial performance, including an easy-to-scan summary of its revenue and earnings trends, in the company report for RadNet.

RadNet’s Bull Case: Growth Engines Firing Together

For a bullish view on RadNet, the Q2 numbers mostly line up. Total revenue rose about 25% year on year, while adjusted EBITDA grew 22.7%, which shows the core imaging business still carries real earnings weight. Digital Health is adding a second growth leg, with revenue up 56.5% and ARR almost doubling to US$105.5m. The slight dip in adjusted EBITDA margin at group level looks more like near term investment, given Digital Health is still ramping and segment EBITDA is already positive.

RadNet Bear Case: Profitability And Leverage Friction

The cautious view also finds support in these results. Net income roughly halved to US$7.53m and basic EPS fell to US$0.10, despite strong top line growth, which points to ongoing pressure from costs, integration and interest. Digital Health ARR growth is strong, yet segment EBITDA remains modest relative to revenue, so the AI story is not translating into large profit yet. The added US$250m term loan may worry investors who already focus on capital intensity, even though net debt to EBITDA of 1.8x still sits at a moderate level.

After interest coverage and insider selling both raise questions about risk appetite, review the independent risk analysis for RadNet which shows 2 important warning signs to see what else might matter.

Stay Ahead Of Your Next Move

If RadNet's record Q2 revenue and fast growing digital health ARR have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a potential entry point. Once you are invested, use the Portfolio Command Center to cut through market noise and focus on the key updates that matter most to your holdings. For a longer term view, tap into thousands of investor perspectives through the Community and see how others are thinking about stocks like RadNet. By spotting hidden catalysts and potential risks early, you can make decisions faster and stay a step ahead of the market.

Seeking Alternatives Beyond RadNet Now

Fresh ideas do not stay under the radar for long. Spot stocks building breakout momentum before the crowd, while the data still matters and sentiment has not fully caught up. Act now.

• Spot cash rich compounders that could hold up when markets turn by scanning our curated list of solid balance sheet and fundamentals stocks (48 results) before others catch on.
• Track the AI infrastructure build out early by following the hand picked 56 AI infrastructure stocks that may benefit if spending on chips, power and data centers remains strong.
• Position ahead of the next robotics upgrade cycle with carefully filtered 37 robotics and automation stocks while many of these automation plays are still being priced as yesterday's industrials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.